On the other hand, preclinical studies in rodents have shown that co-administration of a long-acting GIPRA synergistically enhances the glucose-lowering and weight-reducing effects of GLP-1RA (44, 75)
Glucagon-like peptide-1: a key regulator of innate immune function with clinical efficacy in a range of inflammatory diseases
[DOI] [PMC free article] [PubMed] [Google Scholar] 23
Patents are already being filed for combinations of GLP-1s with myostatin inhibitors
A separate analysis of the STEP 1 data found that lean mass was reduced by 6.92 kg with a total weight reduction of 15.3 kg, meaning roughly 45 percent of the weight lost was lean mass
Furthermore, among those already with a SUD, GLP-1s appeared to lower hospitalizations, overdoses, and death, GLP-1 receptor agonists are not replacements for current medication treatments for AUDbut may soon become important additions